Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 400 • 2013 ACR/ARHP Annual Meeting
Parotid Ultrasound Abnormalities Among Rheumatoid Arthritis Patients: Prevalence and Clinical Correlates
Hong Yang¹, Doquyen H. Huynh², Arnold Ceponis³ and Arthur Kavanaugh⁴, ¹Rheumatology, UCSD, San Diego, CA, ²Rheumatology, UC San Diego School of Medicine, San Diego, CA, ³Medicine/Rheumatology, University of California San Diego, La Jolla, CA, ⁴University of California San Diego, San Diego, CA
Background/Purpose: Sjögren's syndrome (SS) occurs commonly among rheumatoid arthritis (RA) patients. It may be an indicator of, and even a contributor to, increased RA disease…
Abstract Number: 2810 • 2013 ACR/ARHP Annual Meeting
Follow-Up Testing Of Interferon-Gamma Release Assays For The Diagnosis Of Hidden Tuberculosis Infection In Patients Receiving Tumor Necrosis Factor Alpha Antagonists
Chan-Nam Son¹, Tae-Hwan Kim², Il-Hoon Sung³, Jae-Bum Jun² and Dae-Hyun Yoo², ¹Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Orthopaedic surgery, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Anti-tumor necrosis factor alpha (Anti-TNFα) therapy is often used in patients with rheumatic diseases who do not respond to conventional treatment. Risk of tuberculosis…
Abstract Number: 2295 • 2013 ACR/ARHP Annual Meeting
Mortality In Early Rheumatoid Arthritis Comparing Lithuania and Finland. A 13-Year Follow Up
Tuulikki Sokka¹, Sigita Stropuviene², Hannu Kautiainen³, Tuomas Rannio⁴ and Jolanta Dadoniene², ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Vilnius Univ, Vilnius, Lithuania, ³Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁴Jyvaskyla Central Hospital, Jyväskylä, Finland
Background/Purpose: Life span of patients with rheumatoid arthritis (RA) is reduced by 3-10 years compared to non-RA population. Only recent reports indicate improvements in survival…
Abstract Number: 1404 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking On Joint Physiology In Men and Mice
Caroline Ospelt¹, Giovanni Camici², Anna Engler³, Christoph Kolling⁴, Renate E. Gay⁵, Beat A. Michel⁶ and Steffen Gay¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Institute of Physiology, University of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Schultess Clinic, Zurich, Switzerland, ⁵Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Smoking is a major risk factor for the development of anti-citrullinated protein antibodies positive rheumatoid arthritis (RA) in individuals who carry shared epitope alleles.…
Abstract Number: 393 • 2013 ACR/ARHP Annual Meeting
Survival In Rheumatoid Arthritis Associated Pulmonary Arterial Hypertension Is Comparable To Idiopathic Pulmonary Arterial Hypertension
Saghar Sadeghi¹, John T. Granton², Pooneh Akhavan³ and Sindhu R. Johnson⁴, ¹Medicine, Toronto Scleroderma Research Program, Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: To evaluate survival in rheumatoid arthritis associated pulmonary arterial hypertension (RA-PAH) compared to idiopathic PAH (IPAH) patients. Secondary outcomes included evaluation of differences in…
Abstract Number: 2684 • 2013 ACR/ARHP Annual Meeting
Impact Of Anti-Rheumatic Treatment On Immunogenicity Of Pandemic H1N1 Influenza Vaccine In Patients With Arthritis
Meliha C. Kapetanovic¹, Lars-Erik Kristensen², Tore Saxne³, Teodora Aktas⁴, Andreas Mörner⁴ and Pierre Geborek⁵, ¹Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Vaccinology Unit, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden., Vaccinology Unit, Department of Diagnostics and Vaccinology, Swedish Institute for Communicable Disease Control, Solna, Sweden., Solna, Sweden, ⁵Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis Background/Purpose: An adjuvanted pandemic H1N1 influenza (pH1N1) vaccine (Pandemrix®) was…
Abstract Number: 2304 • 2013 ACR/ARHP Annual Meeting
Follow-Up Of Patients With Preclinical Rheumatoid Arthritis – Results Of a Telephone Survey
Pascal Klaus¹, Vivien Köhler¹, Hans Bastian¹, Tanja Braun¹, Eva Gremmelsbacher¹, Vera Höhne-Zimmer¹, Frank Buttgereit¹, Gerd Burmester¹ and Jacqueline Detert², ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany
Background/Purpose: Preclinical rheumatoid arthritis (pre-RA) describes a subset of patients with arthralgia (but no synovitis) where either anti-citrullinated peptide antibodies (ACPA) and/or rheumatoid factor (RF)…
Abstract Number: 1371 • 2013 ACR/ARHP Annual Meeting
Tuberculosis Infection In Patients With Tumor Necrosis Factor–α Antagonists In South Korea;retrospective Analysis Using By National Health Insurance Review and Assessment Service
Jong Wook Beom¹, Eun-Jung Park², Jinseok Kim³, Se Chang Park⁴ and Gi Hyeon Seo⁵, ¹Medicine, Jeju National University Hospital, Jeju, South Korea, ²Internal Medicine, Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Republic of Korea, Jeju, South Korea, ³Internal Medicine, Jeju National University Hospital, Jeju, South Korea, ⁴Veterinary Medicine, Seoul National University, Seoul, South Korea, ⁵Health Insurance Review and Assessment Service, Seoul, South Korea
Background/Purpose: Tumor necrosis factor-α (TNF-α) antagonists bring new hope for treating rheumatoid arthritis (RA) over the past decade. However, the subsequent increased risk of developing…
Abstract Number: 376 • 2013 ACR/ARHP Annual Meeting
The Risk Of Pneumococcal Infections After Immunisation With Pneumococcal Conjugate Vaccine Compared To Non-Vaccinated Inflammatory Arthritis Patients
Johanna Bengtsson¹, Pierre Geborek², Tore Saxne³, Martin Englund⁴, Ingemar F. Petersson⁴, Jan-Åke Nilsson⁵, Göran Jönsson⁶ and Meliha C. Kapetanovic⁷, ¹Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ²Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Lund Universoty, Dept of Clinical Sciences Lund, Section of Infectious Diseases, Lund, Sweden, ⁷Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden
The risk of pneumococcal infections after immunisation with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patientsBackground/Purpose: The purpose was to examine the risk of…
Abstract Number: 2686 • 2013 ACR/ARHP Annual Meeting
Impact of Methotrexate Dose Reduction Upon Initiation of Adalimumab On Clinical and Ultrasonographic Parameters in Patients With Moderate to Severe Rheumatoid Arthritis
Gurjit S. Kaeley¹, Amy M. Evangelisto², Midori Jane Nishio³, Shufang Liu⁴ and Hartmut Kupper⁵, ¹College of Medicine, University of Florida, Jacksonville, FL, ²Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, ³Diablo Clinical Research, Walnut Creek, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Methotrexate (MTX) is the recommended first-line disease-modifying antirheumatic drug (DMARD) for the treatment of moderately to severely active rheumatoid arthritis (RA). Whether patients (pts)…
Abstract Number: 2242 • 2013 ACR/ARHP Annual Meeting
Patient Versus Physician Joint Counts In Rheumatoid Arthritis Utilizing a Unique Self-Joint Examination Tool
Daisy Bang¹, Yomei Shaw², Christine L. Amity³, Kelly A. Reckley⁴, Ilinca D. Metes⁵ and Marc C. Levesque⁶, ¹Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, ²Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ³Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, ⁴Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The quantitative assessment of disease activity has been endorsed by the American College of Rheumatology (ACR) to improve rheumatoid arthritis (RA) outcomes. To facilitate…
Abstract Number: 1356 • 2013 ACR/ARHP Annual Meeting
Disease Activity Of Rheumatoid Arthritis Is Influenced By Seasonal Change, As Analyzed Based On a Nationwide Japanese Cohort Database
Tetsuji Sawada¹, Hiroaki Mori², Kota Shimada³, Haeru Hayashi¹, Koichiro Tahara¹, Jinju Nishino⁴ and Shigeto Tohma⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Rheumatology, Tokyo Meidical University, Tokyo, Japan, ³Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁴Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Previous studies have suggested that environmental factors, such as weather, humidity and seasonal change, may affect rheumatoid arthritis (RA). In the present study, we…
Abstract Number: 357 • 2013 ACR/ARHP Annual Meeting
Predictive Value Of Anti Cyclic Citrullinated Peptide and Rheumatoid Factor To The Development Of Rheumatoid Arthritis In a Cohort Of Healthy Relatives Of Patients With Rheumatoid Arthritis
Jose Dionisio Castillo-Ortiz¹ and Cesar Ramos-Remus², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico
Background/Purpose: Consanguineous relatives of patients with RA are at a higher risk to develop RA. It is also known that specific antibodies including CCP and…
Abstract Number: 2690 • 2013 ACR/ARHP Annual Meeting
Survival Of The Second Biologic After The First Tumor Necrosis Factor Alpha Inhibitor’s Failure In The Treatment Of Rheumatoid Arthritis: Prospective Observational Data From Biorx.Si Registry
ŽIga Rotar¹ and Matija Tomsic², ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia
Background/Purpose: Current recommendations for management of RA propose a tumor necrosis factor alpha inhibitor (TNFi) for patients failing to achieve the treatment target with synthetic…
Abstract Number: 1951 • 2013 ACR/ARHP Annual Meeting
The Spring Ligament Window: A Unique Sonoanatomic View Into a Complex Rheumatoid Joint
Joanne Kitchen¹, I. Moller², Maribel Miguel-Perez³ and David A. Bong⁴, ¹Instituto Poal de Reumatolgia, Barcelona, Spain, ²Instituto Poal, Barcelona, Spain, ³University of Barcelona, Barcelona, Spain, ⁴Instituto Poal de Reumatologia, Barcelona, Spain
Background/Purpose: The calcaneonavicular or spring ligament (SL) is a group of 3 stout non-elastic fibrocartilaginous bands in the medial mid-foot that is important in maintaining…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].